Irbesartan
Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
---|---|---|---|
Angiotensin II Receptor Blockers | Irbesartan | 75-300mg PO Q24H | Administer Anytime During HD; Post HD if Hypotensive |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
---|---|---|---|---|---|---|---|
428 | <5 | 13 | No change | 90 | 0.72 | N/A | 0 (N/A) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB01029
- Inrig J. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010;23(3):290-7.
- Marino M, Vachharajani N. Pharmacokinetics of Irbesartan Are Not Altered in Special Populations. Journal of Cardiovascular Pharmacology. 2002;40:112-122.
- Sica D a, Marino MR, Hammett JL, et al. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clinical pharmacology and therapeutics. 1997;62(6):610-8.